Market Performance - U.S. stocks traded higher, with the Dow Jones index gaining approximately 0.1% on Monday, closing at 45,856.77. The NASDAQ rose 0.75% to 22,307.16, and the S&P 500 increased by 0.37% to 6,608.41 [1] - Consumer discretionary shares experienced a significant increase of 1.9%, while health care stocks fell by 0.5% on the same day [1] Economic Indicators - The New York Empire State Manufacturing Index declined to -8.7 in September, down from 11.9 in August and below market estimates of 5 [2][10] Commodity Prices - Oil prices increased by 1% to $63.31, while gold rose by 0.3% to $3,698.80. Silver decreased by 0.1% to $42.810, and copper saw a rise of 1% to $4.6975 [5] European Market Performance - European shares were mostly higher, with the eurozone's STOXX 600 rising by 0.47%. Spain's IBEX 35 Index increased by 0.63%, while London's FTSE 100 fell slightly by 0.01%. Germany's DAX 40 gained 0.27%, and France's CAC 40 rose by 1.05% [6] Asian Market Performance - Asian markets closed mostly mixed, with Hong Kong's Hang Seng rising by 0.22%, China's Shanghai Composite falling by 0.26%, and India's BSE Sensex declining by 0.15% [7] Company News - Check-Cap Ltd. (CHEK) shares surged by 261% to $2.68 following a definitive merger agreement with MBody AI. Helius Medical Technologies, Inc. (HSDT) shares increased by 161% to $19.70 after announcing a $1.25 billion SOL-backed treasury strategy with an oversubscribed PIPE offering at $6.88 per share [9] - Robo.ai Inc. (AIIO) shares rose by 43% to $2.0850 after signing a joint venture agreement to establish Robo.ai Industrial City in Dubai [9] - aTyr Pharma, Inc. (ATYR) shares plummeted by 81% to $1.1694 after failing to meet primary endpoints in a Phase 3 study [9] - Avidity Biosciences, Inc. (RNA) shares fell by 7% to $41.68 following a filing for an offering of 15 million shares of common stock [9] - The Hain Celestial Group, Inc. (HAIN) shares dropped by 26% to $1.5894 after reporting worse-than-expected fourth-quarter financial results [9]

Group 1: Rewey Asset Management Overview - Rewey Asset Management's "RAM Smid Composite" increased by 6.11% in Q2 2025, slightly underperforming the benchmark Russell 2500 Value Total Return Index, which gained 7.29% [1] - Year-to-date, the composite returned -1.29%, compared to a 1.03% gain for the benchmark [1] - The firm expresses confidence in the Smid value sector as it approaches the second half of 2025 [1] Group 2: Orthofix Medical Inc. Analysis - Orthofix Medical Inc. (NASDAQ:OFIX) is highlighted as a key stock, with a one-month return of 2.76% and a 52-week loss of 9.80% [2] - As of September 12, 2025, Orthofix's stock closed at $14.91 per share, with a market capitalization of $588.86 million [2] - Rewey Asset Management increased its position in Orthofix Medical Inc. in Q2 2025, following a 45.6% decline from its February high and a 36.1% drop from its 2024 close, viewing it as a compelling valuation opportunity [3] Group 3: Hedge Fund Interest and Comparisons - Orthofix Medical Inc. was held by 25 hedge fund portfolios at the end of Q2 2025, down from 28 in the previous quarter [4] - While Orthofix is acknowledged for its investment potential, the firm believes certain AI stocks present greater upside potential and less downside risk [4]

Group 1 - Boston Scientific Corporation (BSX) is recognized as one of the best defensive stocks to buy, with an upgrade from Oppenheimer to 'Outperform' and a price target of $125 [1][2] - The company has shown a strong performance with a revenue growth of 21.44% over the past 12 months, supported by a robust merger and acquisition strategy [2] - Boston Scientific is projected to have a compound annual growth rate (CAGR) of 11%-13%, indicating a positive outlook for a highly diversified company in the healthcare sector [3] Group 2 - The company achieved a 17% organic revenue growth in the second quarter of 2025, with earnings per share increasing by 23% [3] - Boston Scientific develops and manufactures innovative medical devices and solutions for various complex medical conditions, including cardiovascular, respiratory, digestive, neurological, and urological diseases [4]

Core Insights - GE HealthCare Technologies Inc. (GEHC) has a market capitalization of $34.9 billion and operates in various healthcare segments, including Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics [1] - The company focuses on integrating AI, digital platforms, and data analytics to enhance efficiency and clinical outcomes, emphasizing precision care for personalized diagnosis and treatment [2] Stock Performance - GE HealthCare's stock is currently trading 19.4% below its 52-week high of $94.80, recorded on February 13, and has increased by 4.6% over the past three months, outperforming the Dow Jones Industrial Average's 6.7% rise during the same period [3] - Year-to-date, GEHC's stock has decreased by 2.2%, while the Dow Jones has risen by 7.7%. Over the past 52 weeks, GEHC shares have dropped 12.6%, underperforming the Dow Jones's 11.5% returns [4] Recent Developments - On September 10, GE HealthCare announced its plan to acquire icometrix, a company specializing in AI-powered brain imaging analysis for neurological disorders, which will enhance GEHC's MRI systems and support personalized treatment planning [5] - This acquisition aligns with GE HealthCare's precision care strategy by expanding its neuro solutions portfolio and improving clinical decision support in neurological care, resulting in a 2.6% increase in its shares in the following trading session [6]

央视网消息：一支笔可以筛查帕金森病，一台眼底照相机可以提示高血压、脑梗风险。这些医疗新科技将如何赋能我们的健康管理，马上去服贸会现场一探 究竟。 总台央视记者王舒畅：我手中这支笔，看起来普通，但内置很多传感器。只要拿起它，根据系统的指示音做出举起、旋转和书写的动作，它就能辅助帕金森 病的早期筛查和用药指导，产品明年将会上市。 参展商任培：可以检测持笔的手细微抖动情况，握笔的时候手部的肌肉压力，我们可以从中提取出一些参数，作为一个帕金森病早期筛查判断的数据。用户 在家里可以把检测结果发送给他的主治大夫，不用去医院。 AI眼底照相机，在服贸会最受老年观众的关注。只需在设备前拍摄一张眼底照片，就能生成关于高血压、糖尿病、心梗、脑梗等方面的风险数值报告。 这粒胶囊大小的设备是用于消化系统检查的内窥镜。患者服用后，它会拍摄上万张照片，然后以全景图式呈现，甚至可以实现远程发送 。 在服贸会现场有很多和中医有关的AI产品。这款导诊仪数字人叫"安安"。它能通过多轮问诊推荐科室，还可以结合节气给出中医调理建议。它的智慧来自中 医垂直大模型，目前这样的大模型已经在北京一些医院落地。 当前，人工智能和大数据等前沿技术正在重塑医疗健 ...

央视网消息：一支笔可以筛查帕金森病，一台眼底照相机可以提示高血压、脑梗风险。这些医疗新科技将如何赋能我们的健康管理，马上去服贸会现场一探 究竟。 这粒胶囊大小的设备是用于消化系统检查的内窥镜。患者服用后，它会拍摄上万张照片，然后以全景图式呈现，甚至可以实现远程发送 。 在服贸会现场有很多和中医有关的AI产品。这款导诊仪数字人叫"安安"。它能通过多轮问诊推荐科室，还可以结合节气给出中医调理建议。它的智慧来自中 医垂直大模型，目前这样的大模型已经在北京一些医院落地。 当前，人工智能和大数据等前沿技术正在重塑医疗健康服务模式。未来，随着这些创新成果的推广应用，医疗服务的质量有望进一步提升。 总台央视记者 王舒畅：我手中这支笔，看起来普通，但内置很多传感器。只要拿起它，根据系统的指示音做出举起、旋转和书写的动作，它就能辅助帕金 森病的早期筛查和用药指导，产品明年将会上市。 参展商 任培：可以检测持笔的手细微抖动情况，握笔的时候手部的肌肉压力，我们可以从中提取出一些参数，作为一个帕金森病早期筛查判断的数据。用 户在家里可以把检测结果发送给他的主治大夫，不用去医院。 AI眼底照相机，在服贸会最受老年观众的关注。只需在设备 ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 13, 2025 /PRNewswire/ --Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596, and pending in the Central District of California – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses ...

Market Overview - U.S. stocks showed mixed performance, with the Dow Jones index falling over 200 points, down 0.44% to 45,904.50, while NASDAQ rose 0.41% to 22,134.26 and S&P 500 gained 0.01% to 6,587.98 [1] - European shares were mixed, with the eurozone's STOXX 600 rising 0.10% and Spain's IBEX 35 Index falling 0.31% [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 0.89% and Hong Kong's Hang Seng rising 1.16% [7] Consumer Sentiment - The University of Michigan consumer sentiment declined to 55.4 in September from 58 in August, below market estimates of 58 [2][8] Commodities - Oil prices increased by 1.7% to $63.44, gold rose 0.5% to $3,691.50, silver increased by 1.5% to $42.765, and copper rose 0.2% to $4.6680 [5] Company Performance - Allied Gaming & Entertainment Inc. shares surged 113% to $1.9501 after announcing an initial investment in Bitcoin and Ethereum [9] - GlucoTrack, Inc. shares rose 80% to $8.76 following a purchase agreement with Sixth Borough Capital for up to $20 million [9] - IBEX Limited shares increased by 40% to $42.77 after reporting better-than-expected fourth-quarter results and issuing FY26 sales guidance above estimates [9] - Next Technology Holding Inc. shares dropped 54% to $0.1638 after announcing a 200-for-1 reverse stock split [9] - XTI Aerospace, Inc. shares fell 33% to $1.3698 after pricing a $20 million public offering [9] - Frequency Electronics, Inc. shares decreased by 13% to $29.95 after reporting worse-than-expected first-quarter results [9]

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025. RxSight describes itself as a "commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses.†For more information, submit a form, email attorney Phillip Kim, or gi. ...

Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 (“FQ1 2026”) and provided a business update highlighting continued progress. First Quarter and Recent Highlights HeartSciences has made substantial prog ...